donepezil has been researched along with bis(7)-tacrine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Campiani, G; Catalanotti, B; Chiasserini, L; Fattorusso, C; Gaeta, A; McKissic, D; Novellino, E; Pellerano, C; Savini, L; Saxena, A | 1 |
| Agnusdei, M; Belinskaya, T; Butini, S; Campiani, G; Catalanotti, B; Fattorusso, C; Fedorko, JM; Gaeta, A; Gemma, S; Greig, NH; Holloway, HW; Nacci, V; Novellino, E; Persico, M; Savini, L; Saxena, A | 1 |
| Lv, W; Xue, Y | 1 |
| Andrisano, V; Apperley, KYP; Bartolini, M; Baschieri, A; Basso, M; Chen, HH; De Simone, A; Guardigni, M; Keillor, JW; Kobrlova, T; Milelli, A; Montanari, S; Soukup, O; Valgimigli, L | 1 |
| Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A; Podkowa, A; Sałat, K; Šink, R; Stojan, J; Trontelj, J; Žakelj, S; Živin, M | 1 |
| Kumar, A; Mishra, P; Panda, G | 1 |
| Bartolini, M; Benkova, M; Bolognesi, ML; Brazzolotto, X; Caliandro, R; Chalupova, K; Chvojkova, M; Dolezal, R; Gastellier, AJ; Habartova, L; Hepnarova, V; Hrabinova, M; Jarosova, M; Jost, P; Jun, D; Kleteckova, L; Korabecny, J; Kristofikova, Z; Kuca, K; Lamba, D; Mezeiova, E; Misik, J; Monti, B; Muckova, L; Mzik, M; Nachon, F; Nepovimova, E; Pejchal, J; Pesaresi, A; Setnicka, V; Soukup, O; Uliassi, E; Vales, K; Valis, M; Zdarova Karasova, J | 1 |
| Du, C; Du, K; Feng, C; Lv, W; Shen, R; Sun, H; Xi, M | 1 |
1 review(s) available for donepezil and bis(7)-tacrine
| Article | Year |
|---|---|
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Ligands; Neuroprotective Agents | 2019 |
7 other study(ies) available for donepezil and bis(7)-tacrine
| Article | Year |
|---|---|
Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Ligands; Models, Molecular; Structure-Activity Relationship; Tacrine | 2003 |
Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
Topics: Acetylcholinesterase; Acridines; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; In Vitro Techniques; Ligands; Models, Molecular; Molecular Probes; Structure-Activity Relationship | 2005 |
Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.
Topics: Algorithms; Artificial Intelligence; Cholinesterase Inhibitors; Computational Biology; Drug Design; Models, Chemical; Quantitative Structure-Activity Relationship | 2010 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; Glycogen Synthase Kinase 3 beta; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2017 |
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
Topics: Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Crystallography, X-Ray; Drug Design; Female; Humans; Kinetics; Male; Mice; Models, Molecular; Protein Binding; Protein Conformation; Rats; Safety; Thermodynamics; Tissue Distribution | 2018 |
Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Ligands; Male; Maze Learning; Molecular Structure; Neuroprotective Agents; Protein Aggregates; Rats; Rats, Wistar; Structure-Activity Relationship; Tacrine; Tryptophan | 2019 |
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2022 |